SEDATION & NEUROMUSCULAR BLOCKADE Pediatric Critical Care Medicine Emory University Children’s Healthcare of Atlanta.
Post on 25-Dec-2015
218 Views
Preview:
Transcript
SEDATION & NEUROMUSCULAR
BLOCKADE
Pediatric Critical Care Medicine
Emory UniversityChildren’s Healthcare of
Atlanta
2
Objectives• Definition• Signs & Symptoms• Categories• Shock physiology• Treatments
3
Myths • Children don’t feel pain/anxiety; underestimation
of pain• Masking symptoms of progressing injury• Side effects: respiratory depression &
cardiovascular compromise• Addiction
4
Truths - Pain• Pathophysiology of pain
Tissue damage release local mediators (bradykinin, substance P, prostoglandins, K+) heighten nociception facilitate the communication of painful sensations to the spinal cord & brain
Tissue injury release of histamine & serotonin increase pain sensitivity in areas surrounding the site of initial injury
5
Truths - Pain• All nerve pathways for the conduction of painful
stimuli & awareness of pain are functional by 24 wk EGA
• Failure to manage painful stimuli increases perception of pain for future painful events
• Lack of pain control increases the stress responses
» Simons SH, van Dijk M. van Lingen RA et al: Randomized controlled trial evaluation effects of morphine on plasma adrenaline/noradrenaline concentration in newborns. Arch. Dis Child Fetal Neonatal Ed. 2005; 90: F36-F40
6
Truths – Side Effects• Respiratory & hemodynamic compromises
– Potentiates with combination with other sedatives & analgesics
– Understanding the pharmacokinetics and effects of these agents
7
Truths - Addiction• Definitions:
– Addiction– Tolerance– Dependence
• Dependence: – 1/3 pts who received tx>4wks– Continuous infusion: tolerance develops within days
» Riss, J.; Cloyd, J.; Gates, J.; Collins, S. (Aug 2008). "Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.". Acta Neurol Scand 118 (2): 69–86. doi:10.1111/j.1600-0404.2008.01004
• Risk factors:– Dependent personality– Short acting benzo– Long-term use of benzo
8
Sedation – A Continuum
• Analgesia• Minimal sedation• Moderate sedation• Deep sedation• General anesthesia
9
Awake/ Drowsy/Gen. Anest.
Baseline AnxiolysisModerate Deepsedation sedation
Sedation – A Continuum
10
Sedation Measurement Tools
• Modified Ramsey Score– 0 – unresponsive– 1 – responsive to noxious stimuli– 2 – responsive to touch or name– 3 – calm & cooperative– 4 – restless & cooperative– 5 – agitated– 6 – dangerously agitated & uncooperative
11
Sedation Measurement Tools
• Bispectral Index (Bis)– Measure level of consciousness by algorithmic analysis of
EEG– Scale 0 (silent EEG) to 100 (fully awake)– Good tools to use for deep sedation/anesthesia, doesn’t
differentiate level of consciousness for moderate to deep sedation
– Mason KP et all: Value of bispectral index monitor in defferentiating between moderate and deep Ramsay Sedation Scores in children. Paediatr Anaesth. 2006 Dec; 16 (12):1226-31
12
Sedative - Hypnotic• Sedation, motion control, and anxiolysis• NO analgesia• Classes
– Benzodiazepines– Barbiturates– Chloral hydrate– Diprivan– α –adrenergic agonists
13
Sedation Neurotransmitters
• GABA: inhibitory neurotransmitter in the brain• Glycin: inhibitory neurotransmitter in the spinal
cord & brain stem• Glutamate: excitatory receptors
14
Sedation - Benzodiazepines• Augment GABA & glycin transmission binding
to receptors influx Cl- hyper-polarization resistance to neuronal excitation
• BZD bind to receptor complex enhance GABA binding to its receptors increase in GABA efficiency
• BZD increase the frequency of Cl- channel opening increase GABA potency
15
Sedation - Benzodiazepines• Effects: anxiolytic, amnestic, anti-convulsant,
hypnotic, sedative, skeletal muscle relaxant
• Decrease CMRO2 & CBF
• Impair anterograde amnesia,• Affect ventilatory response to both hypoxia &
hypercapnea• Potentiate effect with alcohol & narcotics• Decrease both pre & after-load decrease MAP
with min effect on CO
16
Sedation - Benzodiazepines• Tolerance involves GABAA receptor
– Down regulation– Alterations to the subunit configuration– Uncoupling & internalizing of the BZD binding site– Change in gene expression
• Others– Paradoxical reaction – disinbition usually in children or
older adults with h/o alcohol abuse or ones with underlying aggressive behavior
– Rebound insomnia & anxiety after only 7 days– Long lasting memory deficit with long term use – Worsening of depression
17
Sedation - Benzodiazepines• Withdrawal syndrome
– Anxiety, insomnia, nightmares, seizures, psychosis, hyper-reflexia
– Post midazolam infusion phenomenon– Slow tapering to decrease withdrawal
T ½Hr
ProteinBinding
Active metab. Metabolism
Midazolam 1-4 94% alpha1-hydroxymidazola
m
P450Glucoronide conjugation
Lorazepam 14.5 91% None Hepatic glucuronidatio
n
Diazepam 46.6 97.8% Desmethyl diazepam (t½
48-96 hrs)
Liver
Sedation - Benzodiazepines
19
BZD - Midazolam• Most commonly used sedative • Water soluble (less thrombophlebitis) less pain
with injection• IV, IM, PO, IN, PR, Buccal• Metabolized by P450 (CYP) enzymes & by
glucuronide conjugation• Side effects:
– Post midazolam infusion phenomenon– A “midazolam infusion syndrome”: delayed arousal hrs
to days after discontinuation, associated with high dose infusion
– “Hang over”: psychomotor & cognitive function impairment to the next day
20
BZD - Lorazepam• Highly protein bound, extensively metabolized
into inactive forms• Lipophobic confine in the vascular space• IV, IM, PO, SL• Solvent: polyethylene & propylene glycol
hyperosmolar metabolic acidosis with prolonged infusion
• Injectable solution contains benzyl alcohol• Uses:
– Status epilepticus– Alcohol withdrawal syndrome, catatonia– Anti-emetic
21
BZD - Diazepam• IV, IM, PO (100% bio-availability), PR (90%)• Highly protein bound, cross BBB & placenta,
excrete in stools• Lipophilic evenly distributed accumulative
effect with repeat doses• High risk of thrombophlebitis, pain with injection• P450 + glucuronidation in liver long t ½
metabolite • Uses: anxiety, insomia, seizure, muscle spasm,
restless leg syndrome, alcohol and BZD withdrawal
22
Sedation - Barbiburates• GABAA receptor (different from BZD) increases duration
of Cl- channel opening increases GAGA efficacy• Block AMPA receptor (glutamate subtype)
• Decrease CMRO2 & CBF
• Side effects: myocardial depression, hypotension• Effects: CNS depressants (mild sedation anesthesia);
anxiolytic, hypnotic, anti-convulsants (except Methohexital)
• Uses:– Surgical anesthesia– Delirium tremens– Seizures– Insomnia
Sedation - Barbiburates
Types Names T ½
Long acting Phenobarbital 24-96 hrs
Medium acting
PentobarbitalSecobarbital
20-45 hrs
Ultra short acting
ThiopentalMethohexital
4-24 hours
24
Sedation - Chloral Hydrate• Sedative & hypnotic: short term use for insomnia• Enhance GABA receptor complex• Tolerance with long term use• Overdose: N/V, convulsion, confusion, irregular
breathing, arrhythmias, coma– SV, junctional or ventricular arrhythmias including
torsades de pointes
• Side effects: rash, gastric discomfort, myocardial depression, hepatic failure– Hyperbilirubinemia: displace bilirubin from albumin sites
Chloral Hydrate Trichloroethanol (TCE)
Trichloroacetate (TCA) Glucuronidation
Alcohol dehydrogenase
T ½ 8-12hr45% protein bound30-60 min peak
T ½ 67 hrsInc. 3-4X in neonatesDisplace bili from albuminCNS depression
Sedation - Chloral Hydrate
26
Sedation - Diprivan• 10% soybean oil, 2.25% glycerol, 1.2% egg
phosphatide• Protein bound; metabolized by conjugation in
liver + extra hepatic elimination
• Potentiate GABAA receptor activity slow the closing of the Cl- channels
• Rapid distribution to peripheral tissue ultra short effects
• T ½ 2-24 hrs
27
Sedation - Diprivan• Adverse effects:
– Pain with injection, pro-bacterial growth, produce green urine
– Negative inotrope, potent vasodilitation, bradycardia– Potent respiratory depressant– Deplete trace element (Zinc) in prolonged infusion– “Propofol infusion syndrome”– “Gasping syndrome”
28
Sedation - α-adrenergic Agonists• α-1 agonist: stimulates phospholipase C activity
– Vasoconstriction, mydriasis– Use a vasopressrs, nasal decongestants, eye exam
• α-2 agonist: inhibits adenylyl cyclase activity– Reduce brainstem vasomotor center-mediated CNS
activation– Use: anti-hypertensive, sedative, opiate & alcohol
withdraw– α-2a: sedation, sleep, analgesia, sympatholysis– α-2b: vasoconstriction, anti-shivering, endogenous
analgesia
29
Sedation - α-adrenergic Agonists• Clonidine: α-2: α-1 = 200:1
– Large volume of distribution, long T½ 12-24 hrs– Acts on receptors in the locus coeruleus (stress & panic)– Prevent pre-synaptic release of NE in the sympathetic
nervous system anti-hypertensive– Acts on peripheral α-2 vasoconstriction
• Dexmetomidine: α-2: α-1 = 1600:1 – T½ 1.5-3 hrs, ½ excrete unchanged in urine– Min respiratory depression, sedated yet easily aroused– Highly lipophilic, cross BBB– Effective in CV symptoms for cocaine intoxication– Reduce sympathetic activity decrease HR & BP– Rapid infusion hypertension due to activation of α-1
30
Sedation - Ketamine• Dissociate anesthesia (similar in structure of PCP)
hallucigenic, analgesic, amnestic• NMDA (glutamate) antagonist analgesic; • Binds to opioid receptors (μ & sigma) in high dose
• Increases catecholamines release & cholinergic receptor stimulation bronchodilator, mucous production, increase SVR, HR, CO
• Increasse CBF & CRMO2
• Metabolized to Norketamine to excrete in urine
31
Analgesia• Oucher Scale by Judy Beyer, modified by Wong: self
report with faces & numerical pain scale
• Pain physiological responses – observational pain scale (OPS)– HR & BP– Measuring level of adrenal stress hormone
• COMFORT score:– Behaviors: alertness, facial tension, muscle tone, agitation,
movement– Physiologic responses: HR, respiration, BP
32
Analgesia• Anti-pyretic & non-opioid• Opiod• Methadone
33
Analgesia – Antipyretic or Non-opioid
• Cyclo-oxygenase (COX) 1,2,3: inhibit prostaglandins production (peripheral & central)– Cox 1:protective prostaglandins preserve gastric
lining integrity; maintain normal renal function– Cox 2: inducible by pro-inflammatory cytokines & growth
factors; in both brain & spinal cord: nerve transmission for pain & fever
• Useful for inflammatory processes (bony or rheumatic)
34
Analgesia – Antipyretic or Non-opioid
• Aspirin:– Alter platelet function; can cause gastric irritant
• Ketorolac– Platelet dysfuncion serious risk of GI bleeding
• Trilisate (choline magnesium trisalicylate; ASA like compound)– No SE on platelet– Use in post-op pain or cancer patients
• Paracetamone– Central Cox 3, no anti-inflammatory activity
• Naproxen– Cox 1 inhibitor
35
Analgesia - Opioids• Terms:
– Agonist– Antagonist– Partial agonist
• Receptors: µΚδσ– Inhibit synaptic transmission in CNS and myenteric
plexus– Found in pre-synaptic, decrease release of excitatory
neurotransmitter for nociceptive stimuli– Coupling with G-protein, regulate trans-membrane signaling by
regulate cAMP
SUB-TYPE
PROTOTYPICDRUGS
ACTIONS
Mu1µ1
Opiates & most opiate peptides
Supraspinal analgesiaProlactin release
Acetylcholine turnover in brain
Mu2µ2
Morphine Respiratory depression; GI transitDopamine turnover in brain
Most CV effects
Deltaδ
Enkephalins Spinal analgesiaDopamine turnover
KappaΚ
Dynorphin Spinal analgesia; sedationInhibition of ADH
Sigmaσ
N-allynormetazocine Psychotomimetic effects
37
Analgesia – Morphine• µ2 agonist: analgesia, sedation, euphoria, resp.
depression• K and δ agonist: spinal analgesia, miosis,
psychomimetic effects• Glucuronide metabolism M3G (exrete) & M6G
(active metabolites)• Poor lipid solubility, protein binding• SQ, IV, IT, epidural
38
Analgesia – Morphine• Increase in sensory threshold for pain• Respiratory depression: decrease RR, MV & response to
CO2• Miosis: pupillary constriction via oculomotor nucleus• Decrease stress hormones: ACTH, ADH, prolactin, GH & epi• Uncertain response to N/V: act on chemo-trigger zone +
depress vomiting center• Smooth muscle relaxation: directly or via vagus nerve• Increase biliary tract tone biliary colic• Urinary retention via increase tone in bladder detrusor
muscle or vesical sphincter• Histamine release bronchospasm or CV collapse
39
Analgesia - Fentanyl• 100X >morphine• Strong agonist at the µ and K• Lipophilic: cross BBB rapid onset with short
duration 2/2 rapid redistribution• Block systemic & pulmonary hemodynamic effect of
pain• Prevent biochemical & endocrine stress (catabolic)• Adverse effects: N/V, constipation, dry mouth,
somnolence, confusion, anesthesia (weakness), sweatingSevere AE: glottic & chest wall rigidity with rapid infusion
(>5mcg/kg)
40
Analgesia – Other Fentanyls
• Sufentanil– 5-10x > Fentanyl, most potent opioid in clinical practice– Smaller volume of distribution, faster recovery after
prolonged infusion
• Alfentanil– 5x < Fentanyl, short duration 5-10 min– Useful for RSI with ICP
• Remifentanil– Metabolized by plasma esterase with short t ½ – Potent µ with mild K & δ effects, potent respiratory
depression, no histamine release– Similar kinetics in neonates & adults– Very expensive
41
Analgesia – Other Opioids• Meperidine
– K receptor agonist; strong opioidergic, anticholinergic and antispasmodic; Local anesthetic properties – surgical spinal analgesia
– Superior to Morphine for billiary spasm or renal colic– Metabolized to normeperidine - twice as toxic– “Serotonin syndrome” with CNS excitatory effects:
tremors, ms spasm, myoclonus, psychiatric changes & seizure
– Interact with MAOIs agitation, delirium, headache, convulsions, hyperthermia (Libby Zion Law)
– Contraindicated in liver, kidney disease, seizure disorder, enlarged prostate or urinary retention, hypothyroidism, asthma, Addison’s disease.
42
Analgesia – Other Opioids• Codein
– Methylmorphine: analgesic, anti-tussive, anti-diarrheal– Alkaloid found in opium poppy (papaveraceae)– Convert to morphine in the liver by P450 and to active
metabolites– Prolonged use physical dependence & psychologically
addictive; mild withdrawal symptoms– Preserve pupillary signs
43
Analgesia – Other Opioids• Tramadol (Ultram, Tramal)
– Weak µ agonist, release serotonin, inhibits reuptake of norepinephrine
– Therapy for most neuralgia and chronic pain– Hard to wean due to effects on opioid, serotonin/NE activity– Decrease seizure threshold
• Hydromorphone (Dilaudid)– Centrally acting opioid class on µ receptor, 8x > morphine– Water soluble with quick onset– Lack of toxic metabolite, lower dependency, less nausea– Brief but intense withdrawal
RELATIVE POTENCY
T½(Hr)
ACTIVEMETABOLITES
MORPHINE 1 2.2 MORPHINE-6-GLUCURONIDE
MEPERIDINE 0.1 3.2 NORMEPERIDINET1/2 15 HRS
FENTANYL 100 4 NONE
HYDROMORPHONE
7 NONE
SUFENTANIL 500 2.7 NONE
REMIFENTANIL N/A NONE
ALFENTANIL 10 1.2 NONE
METHADONE 1 19 NONE
45
Analgesia – Opioid Antagonist
• Naloxone– Competitive antagonist with high affinity for µ receptor
in CNS rapid onset of withdrawal– IV with fast onset of action; T½ 30-81 min
46
Analgesia – Other• Methadone
– Acts on opioid receptors without the euphoric effects prevent narcotic withdrawal syndrome
– Binds on NMDA (N-methyl-D-aspartate) antagonist against glutamate decrease craving for opioids & tolerance
47
Analgesia – Withdrawal• Neurologic excitability: Sleep disturbances,
agitation, tremors, seizures, choreoartheroid movements
• GI disturbances: V/D• Autonomic dysfunction: hypertension,
tachycardia, tachypnea, fever, frequent yawning, sweating or goose flesh,
48
Neuromuscular Blockade• Large highly charged water - soluble molecules at
physiologic pH can’t cross BBB, placenta, GI• Onset is more rapid & less intense at the
laryngeal muscle (vocal cord) & peripheral muscle
• Diaphragm is the most resistant to paralysis
49
Neuromuscular Blockade• Types
– Depolarizing: mimic action of acetylcholine– Non-depolarizing: competitively block ACH receptors
• Classifications– Short: succinylcholine, mivacurium– Intermediate: atracurium, vecuronium, rocuronium,
cisatracurium– Long: pancuronium, doxacurium, pipecuronium
% of Blocka
de
Clinical Relaxation
Ventilation
0 None; TOF > 0.7
Tetanus sust. @ 50Hz
Normal
Inspiratory force > 50cm H2O
25 Poor; inadequate head lift & leg flexion
Slightly to moderate. Diminished VC
50 Fair Mod. to markedly diminished VCTV may be adequate
75 Good TV diminished
90 Good TV inadequate
95 Very good; adequate for tracheal intubation under light anesthesia
Some diaphragmatic motion
100 Excellent; very good for tracheal intubation
ApneaFurhman, 3rd Edition
Metab./excretion
Onset(min)
Duration
(min)
Dosage(mg/kg)
Infusion
Succinylcholine
Pseudo-cholinest.
1 3-4 IV- 1-2IM-3-4
Mivacurium PlasmaCholinester
.
1-3 9-12 0.2 10-14 mcg/kg/min
Atracurium Hoffmann 1-4 20-35 0.3-0.4 0.6-1.2 mg/kg/hr
Cisatracurium
Hoffmann 2-3 35-45 0.1-0.2 0.06-0.24 mg/kg/hr
Vecuronium LiverRenal exc.
1-3 30-40 0.1 0.06-0.15 mg/kg/hr
Rocuronium LiverRenal exc.
1 30-90 0.5-1 10-20 mcg/kg/min
Pancuronium
LiverRenal exc.
2-3 40-60 0.1 0.02-0.1 mg/kg/hr
Pipecuronium
LiverRenal exc.
Doxacurium Renal 5-11 30 0.03-0.05
6-12 mcg/kg/hr
52
NMB: Depolarizing• Succinylcholine
– Stimulates all cholinergic receptors – Binds directly to the postsynaptic ACH receptors– Metabolized by pseudocholinesterase– Also binds to muscarinic receptors of SA node
negative inotrope and chronotrope– Short duration due to high volume of distribution– Prolonged & repeat exposure membrane can
repolarize but remain refractory to subsequent depolarization “Phase II block”, clinical resemblance to non-depolarizing agents.
– Prolonged effects in hepatic dysfunction, hyper-magnesia & pregnancy
53
NMB: DepolarizingSuccinylcholineContraindications
– History of malignant hyperthermia (personal or family)– Neuromuscular disease involving denervation– Muscular dystrophy– Stroke over 72 hours old– Rhabdomyolysis– Burn over 72 hours old– Significant hyperkalemia
54
NMB: Depolarizing
SuccinylcholineMalignant hyperthermia:
– Myopathic metabolic disorder– Autosomal dominant– Sympathetic hyperactivity, mucular rigidity acidosis and
hyperthermia– Uncontrolled increase in skeletal muscle oxidative
metabolism hypoxia, hypercapnea and hyperthermia– Treatment: dantrolene, cooling and sedation
55
NMB: DepolarizingSuccinylcholine
Side effects– Trismus: masseter muscle spasm (can associate with
MH)– Fasciculations: via nicotinic activation – Bradycardia: via muscarinic activation at SA node
especially children; can occur in adults in repeated dose or infusion
– Rhabdomyolysis and muscle pain– Transient ocular hypertension: safe in open globe injury
if use in conjunction with sedation– Mild increase in intra cranial pressure
56
NMB: Non-Depolarizing• Competitively inhibits the postsynaptic Ach
receptors of the neuromuscular motor endplate• Prevents depolarization & inhibits all muscle
function• Categories
– Benzylisoqyinolinium: atracurium, mivacurium» Histamine release» Can cause autonomic ganglionic blockade
– Aminosteroids: rocuronium, vecuronium, pancuronium
57
NMB: Non-Depolarizing• Low plasma protein binding capacity• 4 routes of elimination: renal excretion, hepatic
excretion, biotransformation, tissue binding• Types
– Short: Mivacurium– Intermediate: atracurium, Vecuronium, Rocuronium,
cisatrocurium– Long: d-tubocurarine, pancuronium, pipecuronium,
doxacurium
58
NMB: Non-Depolarizing reversal
• Abx, hypotension, hypothermia, acidosis & hypocalcemia prolong or potentiate NMB
• Duration of reversals are the same in all 3 classes• Neostigmine
– 25-70 mcg/kg
• Edrophonium– Faster acting– 125-250 mcg/kg
top related